Clicky

Sanofi(SNY) News

Date Title
Dec 7 Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Dec 7 REFILE-UPDATE 1-Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline
Dec 7 Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
Dec 6 Merck KGaA Plunges as Multiple Sclerosis Drug Fails in Trial
Dec 5 UPDATE 2-Merck KGaA suffers major blow as MS drug fails in late-stage trials
Nov 30 2 Biotech Stocks You Can Buy and Hold for the Next Decade
Nov 30 Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Nov 28 UPDATE 2-White House urges RSV immunization makers to meet demand
Nov 27 Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Nov 27 How the high-stakes world of Formula 1 racing inspired Sanofi CEO Paul Hudson to deliver more medicines
Nov 27 Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
Nov 27 Regeneron, Sanofi to seek new Dupixent approval in US after COPD success
Nov 27 Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Nov 27 Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Nov 26 12 Best Diabetes Stocks To Buy Now
Nov 25 3 Top Dividend Champions With Market-Beating Yields
Nov 15 Biotech raises funds to find cancer treatments using transgenic mice
Nov 15 MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress
Nov 10 AstraZeneca prioritizes US for RSV drug amid surge in cases
Nov 10 Optum Rx moves 8 insulins to preferred formulary status as pressure mounts on PBMs